A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Vedolizumab in Indian Patients With Ulcerative Colitis and Crohn's Disease
Latest Information Update: 29 Mar 2024
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Takeda
- 26 Mar 2024 Status changed from active, no longer recruiting to completed.
- 26 Jan 2023 Planned End Date changed from 31 Oct 2023 to 10 May 2024.
- 26 Jan 2023 Planned primary completion date changed from 31 Jul 2023 to 30 Jan 2024.